Engineered platelets as targeted protein degraders and application to breast cancer models – Nature Biotechnology
Sakamoto, K. M. et al. PROTACs: chimeric molecules that target proteins to the Skp1–Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Google Scholar
Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273–281 (2023).
Google Scholar
Alabi, S. B. & Crews, C. M. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, 100647 (2021).
Google Scholar
Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Google Scholar
Chen, Y. et al. Small-molecule ferritin degrader as a pyroptosis inducer. J. Am. Chem. Soc. 145, 9815–9824 (2023).
Google Scholar
Wei, J. et al. Harnessing the E3 ligase KEAP1 for targeted protein degradation. J. Am. Chem. Soc. 143, 15073–15083 (2021).
Google Scholar
Imaide, S. et al. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nat. Chem. Biol. 17, 1157–1167 (2021).
Google Scholar
Caianiello, D. F. et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat. Chem. Biol. 17, 947–953 (2021).
Google Scholar
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Google Scholar
Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C. & Voisin-Chiret, A. S. PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today 28, 103395 (2023).
Google Scholar
Chen, Y. et al. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chem. Soc. Rev. 51, 5330–5350 (2022).
Google Scholar
Garber, K. The PROTAC gold rush. Nat. Biotechnol. 40, 12–16 (2022).
Google Scholar
Ahn, G. et al. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382, eadf6249 (2023).
Google Scholar
Gadd, M. S. et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13, 514–521 (2017).
Google Scholar
Takahashi, D. et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. Cell 76, 797–810.e10 (2019).
Li, Z. et al. Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 575, 203–209 (2019).
Google Scholar
Stanton, B. Z., Chory, E. J. & Crabtree, G. R. Chemically induced proximity in biology and medicine. Science 359, eaao5902 (2018).
Google Scholar
Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498–511.e17 (2019).
Chirnomas, D., Hornberger, K. R. & Crews, C. M. Protein degraders enter the clinic—a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20, 265–278 (2023).
Google Scholar
Wurz, R. P. et al. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat. Commun. 14, 4177 (2023).
Google Scholar
Tamura, T. et al. Rapid labelling and covalent inhibition of intracellular native proteins using ligand-directed N-acyl-N-alkyl sulfonamide. Nat. Commun. 9, 1870 (2018).
Google Scholar
Beerkens, B. L. H. et al. N-Acyl-N-alkyl sulfonamide probes for ligand-directed covalent labeling of GPCRs: the adenosine A2B receptor as case study. ACS Chem. Biol. 19, 1554–1562 (2024).
Google Scholar
Kawano, M. et al. Lysine-reactive N-acyl-N-aryl sulfonamide warheads: improved reaction properties and application in the covalent inhibition of an ibrutinib-resistant BTK mutant. J. Am. Chem. Soc. 145, 26202–26212 (2023).
Google Scholar
Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106, 8368–8373 (2009).
Google Scholar
Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18, 345–360 (2017).
Google Scholar
Cuesta, A., Wan, X., Burlingame, A. L. & Taunton, J. Ligand conformational bias drives enantioselective modification of a surface-exposed lysine on HSP90. J. Am. Chem. Soc. 142, 3392–3400 (2020).
Google Scholar
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
Google Scholar
Zhou, X. et al. Therapeutic targeting of BET bromodomain protein, BRD4, delays cyst growth in ADPKD. Hum. Mol. Genet. 24, 3982–3993 (2015).
Google Scholar
Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
Google Scholar
Wang, C. et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat. Biomed. Eng. 1, 0011 (2017).
Hu, Q. et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat. Biomed. Eng. 5, 1038–1047 (2021).
Google Scholar
Wang, Y. et al. Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. Sci. Adv. 9, eadf6854 (2023).
Google Scholar
Michael, J. V. et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood 130, 567–580 (2017).
Google Scholar
Zengerle, M., Chan, K. H. & Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10, 1770–1777 (2015).
Google Scholar
Hu, J. et al. Precise conformational control yielding highly potent and exceptionally selective BRD4 degraders with strong antitumor activity. J. Med. Chem. 66, 8222–8237 (2023).
Google Scholar
Jia, H. et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist. Updat. 32, 1–15 (2017).
Google Scholar
Gangi, A. et al. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg. 149, 252–258 (2014).
Google Scholar
Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–549 (2010).
Google Scholar
Wang, X. et al. The regulatory mechanism of HSP90α secretion and its function in tumor malignancy. Proc. Natl Acad. Sci. USA 106, 21288–21293 (2009).
Google Scholar
Li, W. et al. Extracellular HSP90 (eHSP90) as the actual target in clinical trials: intentionally or unintentionally. Int. Rev. Cell Mol. Biol. 303, 203–235 (2013).
Google Scholar
Murshid, A., Gong, J., Stevenson, M. A. & Calderwood, S. K. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev. Vaccines 10, 1553–1568 (2011).
Google Scholar
Hance, M. W. et al. Secreted HSP90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J. Biol. Chem. 287, 37732–37744 (2012).
Google Scholar
Cheng, C. F. et al. Transforming growth factor α (TGFα)-stimulated secretion of HSP90α: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFβ-rich environment during wound healing. Mol. Cell. Biol. 28, 3344–3358 (2008).
Google Scholar
Loppinet, E. et al. Targeted lysosomal degradation of secreted and cell surface proteins through the LRP-1 pathway. J. Am. Chem. Soc. 145, 18705–18710 (2023).
Google Scholar
Prasad, J. M., Migliorini, M., Galisteo, R. & Strickland, D. K. Generation of a potent low density lipoprotein receptor-related protein 1 (LRP1) antagonist by engineering a stable form of the receptor-associated protein (RAP) D3 domain. J. Biol. Chem. 290, 17262–17268 (2015).
Google Scholar
Secli, L., Fusella, F., Avalle, L. & Brancaccio, M. The dark-side of the outside: how extracellular heat shock proteins promote cancer. Cell. Mol. Life Sci. 78, 4069–4083 (2021).
Google Scholar
Li, C. W. et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187–201.e10 (2018).
Patel, S. R., Hartwig, J. H. & Italiano, J. E. Jr. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 115, 3348–3354 (2005).
Google Scholar
Garcia, B. A. et al. The platelet microparticle proteome. J. Proteome Res. 4, 1516–1521 (2005).
Google Scholar
Hu, C. M. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015).
Google Scholar
Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20, 33–48 (2023).
Google Scholar
